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Prevention of thrombosis and rethrombosis and enhancement
of the thrombolytic actions of recombinant tissue-type
plasminogen activator in the canine heart by DMP728, a
glycoprotein 1Ib/IIla antagonist
'Benedict R. Lucchessi, aWilliam E. Rote, Edward M. Driscoll & bDun-Xue Mu
Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109-0632, U.S.A.
1 We studied DMP728, a non-peptide glycoprotein (GP) IIb/IIIa receptor antagonist, for prevention of
coronary artery thrombosis or rethrombosis in a chronic canine model subjected to arterial injury.
2 In protocol I, DMP728 (1.0mg kg-', i.v., n = 8) or saline (n = 8) was administered and a 150 JA
anodal current was applied to the intimal surface of the left circumflex coronary artery (LCX). Dogs
were monitored for 6 h and again on each of 5 subsequent days.
3 Ex vivo platelet aggregation was inhibited but returned to baseline day after drug administration.
Thrombus weight was reduced (saline, 20.7 ± 5.0 mg; DMP728 1.7 ± 0.4 mg; P< 0.05), as was infarct
size [saline, 27.5 ± 4.3; DMP728, 1.6 ± 0.7 (per cent left ventricle); P<0.05]. All control animals died by
day 3, while all but one of the treated dogs survived the entire protocol (P <0.05).
4 In protocol II, an LCX thrombus was induced and thrombolytic therapy was initiated 30 min later.
DMP728 (1.0 mg kg-', i.v., n = 8) or saline (n = 8) was administered 5 min after recombinant tissue-type
plasminogen activator infusion had begun. The incidence of reocclusion was reduced by DMP728
(saline, 4/8; DMP728, 1/8). One day after thrombolysis, 7/8 DMP728-treated animals were alive
compared with 1/8 in the control group (P = 0.01).
5 DMP728 inhibited ex vivo platelet aggregation, prevented primary and secondary occlusive thrombus
formation, reduced thrombus weight and infarct size and increased survival in a chronic canine model of
coronary artery thrombus formation. DMP728 is an effective anti-platelet intervention when used as the
singular adjunctive agent in association with thrombolytic therapy.
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Introduction
Pharmacological modulation of platelet reactivity is effective
clinically in the secondary prevention of stroke, myocardial
infarction and vascular death in patients with atherosclerosis
exhibiting symptoms related to impaired perfusion of the
cerebral, coronary or peripheral vasculature (Antiplatelet
Trialists Collaboration, 1988; Harrison, 1990; Cairns et al.,
1992). When used as the sole adjunctive antithrombotic
therapy, conventional platelet-modifying agents are less
effective in preventing platelet-dependent thrombosis associ-
ated with mechanical interventions or thrombolytic therapy
in the management of patients with acute arterial thrombotic
occlusion (Harker, 1986; Schwartz et al., 1988; Grines, 1992).
In the latter instances, failure to prevent arterial reocclusion
despite adjunctive therapy with aspirin and/or heparin sug-
gests the persistence of a residual lesion capable of exerting
an intense thrombogenic stimulus leading to the continued
recruitment of platelets and activation of the coagulation
cascade (Harker, 1987; Becker & Gore, 1991; Chesebro &
Fuster, 1991).
The beneficial effects of thrombolytic therapy for myocar-
dial infarction are well documented (GISSI Trial, 1986; ISIS-
2 1988; TAMI Study Group, 1989; GUSTO Investigators,
1993). However, thrombolytic therapy with either recom-
binant tissue-type plasminogen activator (rt-PA) or strep-
tokinase is associated with reocclusion rates of 5-30% and a
rate of reinfarction of about 4% in the absence of adjunctive
therapy (Cairns, 1990; Cairns et al.,; 1992). The stated
percentages represent reocclusive events in patients who are
receiving concomitant aspirin and/or heparin as adjunctive
therapy. The relatively high incidence of reocclusion raises a
question about the efficacy of heparin and aspirin for the
prevention of reocclusion and suggests the need to develop
more effectve pharmacological interventions to be used in
conjunction with thrombolytic therapy and/or coronary angi-
oplasty.
The present experimental study examines the in vivo anti-
thrombotic effectiveness of DMP728 [cyclo(D-2-aminobuty-
rate-N-methyl-L-arginyl-glycyl-L-aspartyl- 3-aminomethylben-
zoic acid) methanesulphonate; Figure 1], a glycoprotein (GP)
Ilb/IIla antagonist with a high affinity and specificity for the
human and the canine platelet GPIIb/IIIa receptor (Mousa et
al., 1994). The results in two experimental models demon-
strate the efficacy of DMP728 as the sole adjunctive treat-
ment for the prevention of either occlusive primary thrombus
formation in response to severe vessel wall injury or secon-




The studies conform to the Position of the American Heart
Association on Research Animal Use adopted 11 November
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of the University of Michigan (Ann Arbor) University Com-
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Figure 1 Chemical structure of DMP728 [(cyclo(D-2-aminobutyrate-
N-methyl-L-arginyl-glycyl-L-aspartyl-3-aminomethylbenzoic acid) meth-
anesulphonate]. The molecular weight is 656.7 and its water solubility
exceeds 150mg ml'. DMP728 is stable in solution at pH 7.4 and 4.5
when at room temperature. The purity of the research sample used in
this study was certified as being >99.0%.
Animal Medicine. The University of Michigan is accredited
by the American Association of Accreditation of Laboratory
Animal Care, and the animal care and use programme con-
forms to the standards in 'The Guide for Care and Use of
Laboratory Animals', Department of Health, Education and
Welfare Publication no. NIH 78-23.
Model of coronary occlusion
The experimental model used in this investigation is a
modification of one developed by our laboratory for the
study of experimentally induced coronary artery thrombosis.
The experimental procedure results in the formation of a
platelet-rich intravascular thrombus at the site of an elec-
trolytically induced endothelial lesion in proximity to a distal
arterial stenosis. In each of the models studied, occlusive
coronary artery thrombosis developed in response to vascular
injury resulting from application of an anodal current to the
intimal surface of the left circumflex coronary artery. The
model facilitated the evaluation of DMP728 for the preven-
tion of primary occlusive arterial thrombosis as well as
prevention of secondary thrombosis (rethrombosis) after
administration of rt-PA under conditions in which the anti-
platelet agent was the only adjunctive drug used in conjun-
ction with the thrombolytic agent. Neither heparin nor
aspirin was employed at any time in the experimental pro-
tocols present in this report.
Surgical preparation and experimental protocol
The surgical procedures described in this study were con-
ducted using aseptic techniques. Male mongrel dogs weighing
14-20 kg were anaesthetized with sodium pentobarbital
(30 mg kg', i.v.), intubated and ventilated with room air
and positive pressure at a stroke volume of 30 ml kg-' and a
frequency of 12 breaths min- (Harvard Apparatus, South
Natick, MA, U.S.A.). Cannulae were placed in the left
carotid artery for monitoring arterial blood pressure (Sta-
tham P23 pressure transducer, Gould, Oxnard, CA, U.S.A.)
and in the right jugular vein for obtaining blood samples.
The jugular venous cannula was flushed thoroughly with
0.9% sodium/chloride solution for injection after drug
administration or after obtaining blood samples. The heart
was exposed by a left thoracotomy through the fifth intercos-
tal space and was suspended in a pericardial cradle. A
2-3 cm segment of the left circumflex coronary artery was
isolated from surrounding tissue by blunt dissection. The
artery was instrumented with a Doppler flow probe (Model
100, Triton Technology, San Diego, CA, U.S.A.), and in-
dwelling electrode, and a ligature stenosis formed by tying a
suture around an 18 gauge needle and the left circumflex
coronary artery and then withdrawing the hypodermic nee-
dle. The intracoronary electrode consisted of a 30 gauge,
Teflon-insulated, silver-coated, copper wire attached to the
tip of a 25 gauge hypodermic needle. The wire and needle tip
assembly were inserted through the wall of the left circumflex
coronary artery and positioned in a manner that allowed the
uninsulated region of the electrode to remain in contact with
the intimal surface of the wall of the vessel. Proper position-
ing of the electrode in the coronary artery was confirmed by
visual inspection at the end of each experiment. The external
portion of the stimulating electrode and the flow probe wires
were secured to the myocardium with a suture.
The intravascular electrode was connected to the positive
pole (anode) of a dual-channel stimulator (Grass S88 stim-
ulator and a Grass Constant Current Unit, Model CCU1A,
Grass Instrument, Quincy, MA, U.S.A.). The cathode was
connected to a distant subcutaneous site. Application of an
anodal d.c. current to the intimal surface of the circumflex
coronary artery results in a deep, thrombogenic, vascular
lesion (Bates et al., 1992). The current delivered to the cir-
cumflex coronary artery was monitored continuously with an
ammeter and maintained at 150;LA.
Recordings of blood pressure, limb lead II electrocardio-
gram and mean and phasic blood flow velocity from the left
circumflex coronary artery were obtained on a model 7
polygraph recorder (Grass Instrument). The electrocardio-
gram was examined for evidence of ST-segment alterations
coinciding with the fluctuations in coronary artery blood flow
velocity.
Protocol 1: prevention of coronary artery thrombus
formation
The protocol for studies designed to determine the efficacy of
DMP728 for the prevention of primary occlusive coronary
artery thrombosis is shown in Figure 2a. The experimental
protcol was initiated after completion of the surgical instru-
mentation and closure of the thoracotomy incision. The
previously instrumented animals were maintained under
anaesthesia, as described above. The animals were allocated
to receive either saline or DMP728 1.0 mg kg-', i.v. in-
travenously over a period of 5 min. Fifteen minutes later, the
anodal current was applied (150;&A) to the intimal surface of
the left circumflex coronary artery for a maximum period of
3 h or was terminated 10 min after blood flow velocity in the
coronary vessel remained stable at zero flow velocity to verify
having achieved formation of a stable occlusive thrombus.
Blood pressure, heart rate, coronary artery blood flow
velocity and ex vivo platelet aggregation were monitored over
the initial 6 h experimental period. The animals were
returned to their housing facilities in the Unit for Laboratory
Medicine upon completion of the protocol on each of the
days. On the subsequent 5 days, surviving dogs were returned
to the laboratory. The animals were allowed to rest in quiet
surroundings without the use of anaesthesia or sedation.
Recordings of coronary artery blood flow velocity were
obtained to confirm the presence or absence of flow in the
left circumflex coronary artery and the limb lead II electro-
cardiogram was monitored for electrocardiographic changes
suggestive of ischaemic injury. Blood was withdrawn for cell
counts and aggregation studies. The dogs were returned to
the holding rooms each day after completion of the daily
recordings and data acquisition.
Survivors were euthanized on the sixth study day. After
spontaneous death or euthanasia, the chest was opened and
the heart was removed. The left circumflex coronary artery
was dissected free as far as possible and opened long-
itudinally. The intracoronary position of the electrode was
verified and the thrombus was removed and weighed on an
analytical balance. The heart was sectioned from apex to
base in 1.0cm-thick sections that were incubated, without
agitation, in triphenyltetrazolium chloride for 5 min at 37°C.
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Figre 2 (a) Diagrammatic representation of the experimental protocol used to determine the ability of DMP728 to prevent
primary coronary artery thrombosis in response to electrolytic current-induced injury to the vessel wall. Heart rate, coronary artery
blood flow velocity, whole blood cell counts and platelet aggregation were monitored throughout the study. The period of the study
is represented in the figures with the heavy dark line for day I and the broken dark lines representing days 2-6. DMP728 or saline
was administered on day I before the initiation of anodal current application to the left circumflex coronary artery (LCX). (b) A
protocol diagram for studies conducted to determine the ability of DMP728 to prevent secondary thrombus formation (rethrom-
bosis) after rt-PA-induced thrombolysis of a preformed occlusive thrombus in the left circumflex coronary artery (LCX). The LCX
was instrumented with a stimulating electrode, a flow probe and a critical stenosis. The dogs were allowed 9 days to recover from
surgery. Dogs were returned to the laboratory and a thrombus was formed in the LCX. The coronary thrombus was allowed to age
for 30 min and thrombolytic therapy with rt-PA was begun. Five mintues after the start of the graded rt-PA infusion, either
DMP728 or saline was administered as an adjunctive agent. The dogs were monitored for 6 h after the start of thrombolytic
therapy and then daily for I h on each of the five subsequent days. Heart rate, coronary artery blood flow velocity, whole blood
cell counts and platelet aggregation were monitored throughout the study.
The transverse ventricular sections were weighed and traced
onto clear acetate sheets. The red pigmented tissue contain-
ing the precipitated formazan complex was considered to
represent viable tissue, whereas tissue that remained pallid
was considered to be irreversibly injured or infarcted. The
demarcated areas were scanned on a flatbed scanner and
digitized using a Macintosh IIci microcomputer (Apple Com-
puter, Cupertino, CA, U.S.A.) and appropriate software
(MacDraft, Innovative Data Design, Concord, CA, U.S.A.).
Infarct size was expressed as a percentage of total ventricular
mass.
Protocol 2: prevention of rethrombosis after lysis
The protocol for studies designed to determine the efficacy of
DMP728 for the prevention of rethrombosis is shown in
Figure 2b. Animals were instrumented as described prev-
iously and were allowed 9 days to recover from the surgical
procedure to ensure adequate wound healing. The animals
were returned to the laboratory and anaesthetized with intra-
venous sodium pentobarbital (30 mg kg-', i.v.). A cannula
was placed into the left jugular vein for obtaining blood
samples and the injury current (150iMA) was applied to the
left circumflex coronary artery for a maximum period of 3 h
or was terminated 10min after blood flow in the vessel had
remained stable at zero velocity to certify formation of a
stable occlusive thrombus. The thrombus was allowed to age
for 30 min before initiating thrombolytic therapy. The throm-
bolytic agent, recombinant tissue plasminogen activator (rt-
PA), was administered as a graded intravenous infusion ac-
cording to the following regimen: 0.22 mg kg-', i.v. bolus,
followed by 0.72 mg kg- ', i.v. infused over 30 min and,
finally, 0.50 mg kg-', i.v. infused over 90 min. The total int-
ravenous dose of rt-PA was 1.44 mg kg'-. DMP728 (1.0 mg
kg-', i.v.) was administered as a slow intravenous injection
given over 5 min and commencing 5 min after beginning the
rt-PA infusion. Reperfusion was defined as the restoration of
blood flow velocity to 20% of baseline values. Blood pres-
sure, heart rate and coronary artery blood flow velocity were
monitored for the remainder of the 6 h observation period,
after which the animals were placed in their housing facilities
until returned to the laboratory on each of the next 5 days.
b
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Haematological measurements
Blood (20 ml) was withdrawn for platelet studies from the
jugular cannula into a plastic syringe containing 3.2% sod-
ium citrate as the anticoagulant [1:10 citrate-blood (v/v)].
Blood was taken for platelet aggregation and whole blood
cell counts at baseline and 60, 240 and 360 min after the
administration of DMP728 and again on each subsequent
day of the protocol. The platelet count was determined with
an H-10 cell counter (Texas International Laboratories,
Houston, TX, U.S.A.). Platelet-rich plasma (PRP), the super-
natant present after centrifugation of anticoagulated whole
blood at 1000 r.p.m. for 5 min (140 g), was diluted with
platelet-poor plasma (PPP) to achieve a platelet count of
200 000 mm-3. PPP was prepared after the PRP was
removed by centrifuging the remaining blood at 2000g for
10 min and discarding the bottom cellular layer. Ex vivo
platelet aggregation was measured by established spectro-
photometric methods with a four-channel aggregometer
(BioData-PAP-4, BioData Corp., Hatboro, PA, U.S.A.) by
recording the increase in light transmission through a stirred
suspension of PRP maintained at 370C. Aggregation was
induced with arachidonic acid (0.65 mM and 0.325 mM) and
ADP (20 tiM and 5 gM). A subaggregatory dose of adrenaline
(550 nM) was used to prime the platelets before stimulation
(Romson et al., 1980). Values were expressed as percentage
of aggregation, representing the percentage of light transmis-
sion standardized to PRP and PPP samples yielding 0% and
100% light transmission respectively.
Inclusion criteria
Animals to be included in the final protocol satisfied the
following pre-established criteria: (a) a circulating platelet
count of not less than 100,000 mm-3; b) demonstrated ability
for platelets to aggregate in response to arachidonic acid
before administration of DMP728; and (c) absence of heart
worms upon final post-mortem examination.
Drugs
DMP728 used in this study was provided by Du Pont Merck
Pharmaceutical Company, Wilmington, DE, U.S.A. The
recombinant tissue plasminogen activator, rt-PA (Activase),
was purchased from the University of Michigan Hospital
Pharmacy of the University of Michigan Medical Center,
Ann Arbor, MI, U.S.A. All other chemicals used in this
study were obtained from Sigma (St Louis, MO, U.S.A.)
Statistical analysis
The data are expressed as mean ± s.e.mean. Ex vivo platelet
aggregation in response to arachidonic acid and to ADP was
assessed before and after DMP728. The data were analysed
by either paired or group analysis using Student's t test when
applicable; differences were considered significant if P <0.05.
Results
Protocol 1: prevention ofprimary coronary artery
thrombus formation
A total of 16 dogs was entered into protocol 1. Each of the
16 animals met the criteria for inclusion in the protocol.
Eight of the dogs were assigned to each of the treatment
groups, either saline of DMP728. Blood pressure, heart rate
and coronary artery flow velocity were not different between
groups at baseline. The administration of DMP728 had no
effect on either mean arterial blood pressure or heart rate.
Circulating blood cells The effect of DMP728 (1 mg kg-1,
i.v.) on whole blood cell counts, haemoglobin and haemato-
crit are shown in Table 1. No changes were noted in red
blood cell count or haematocrit over the 6 days of the study.
Over the acute post-operative period, white blood cell counts
increased on days 3-6 out of the range of normal laboratory
values, but did not become statistically different from base-
line values. Haemoglobin values were decreased on days 5
and 6 and platelet counts were significantly increased 6 days
after the administration of DMP728. The importance of
these changes are unclear at this time. None of the animals
showed evidence of infection related to the surgical procedure
or abnormal values in body temperature.
Platelet aggregation studies Ex vivo platelet aggregation in
response to adenosine diphosphate (ADP) and arachidonic
acid was determined at baseline and again at 60, 240 and
360 min after DMP728 administration. Ex vivo platelet agg-
regation determinations were repeated on the subsequent
days 2 through 6 (Figure 3). Aggregation to each of the
agonists was inhibited significantly on day 1 among those
animals given DMP728, but remained unaltered from base-
line responses in the saline-treated controls. Ex vivo platelet
aggregation responses to arachidonic acid and ADP were
consistent in the surviving control animals on each of the
subsequent days. Among the animals treated with DMP728,
ex vivo platelet aggregation returned to baseline within the
first 24 h and remained consistent over the next 5 days in the
surviving animals.
Thrombus formation and vessel patency Coronary artery
blood flow velocity was monitored daily with the use of a
chronically implanted Doppler flow probe on the left cir-
cumflex coronary artery. The data are presented graphically
in Figures 4a and 4b. Blood flow velocity in the saline-treated
group (Figure 4a) declined to zero within the 180 min period
of anodal current application and was accompanied by char-
Table 1 Effects of DMP728 (1 mg kg-', i.v.) on whole blood cell counts in the dog
White cell count
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Each value represents the mean ± s.e.mean, n = 8 in each group; *P<0.05 vs baseline values; tsignifies out of normal range, but not
statistically different from baseline values. Normal ranges (canine): red cell count 4.4-6.4, white cell count 5.8-17.8 platelet count
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Figure 3 Adenosine diphosphate (ADP)-and arachonic acid-induced
ex vivo platelet aggregations (mean ± s.e.mean; n = 8) from animals
that received DMP728 (1.0 mg kg-' i.v.). Platelet aggregation studies
were performed at baseline and again at 60, 240 and 360 min after
DMP728 administration. Aggregations also were measured on subse-
quent days 2-6. *P<0.05 vs baseline. EJ, ADP, 209AM; _,
ADP, 59AM; i, arachidonic acid, 0.650mM; C, arachidonic
acid, 0.32 M.
acteristic changes in the lead II electrocardiogram showing
initial depression and then persistent elevation in ST segment.
In seven of the eight saline-treated control animals, the left
circumflex coronary artery remained occluded for the remain-
der of the day, with one animal showing slight, but
measurable, blood flow velocity. By day 6, all control
animals had died, suddenly and without warning.
The administration of the platelet GPIIb/IIIa receptor
antagonist, DMP728, limited the extent of intracoronary
thrombus formation and prevented the subsequent reduction
in coronary artery blood flow velocity as well as the elec-
trocardiographic changes suggestive of regional myocardial
ischaemia and/or injury. In seven of the eight animals
assigned to receive DMP728, coronary artery blood flow
velocity was present on each of the subsequent 5 days. The
one remaining DMP728-treated animal died suddenly and
unexpectedly during the evening of day 5 after being returned
to its holding facilities.
The patency status of individual animals over the 6 day
experimental period is summarized in Figure 5 (a and b). The
open bars signify that the relevant coronary artery is patent.
The hatched bars represent thrombotic occlusion of the cor-
onary artery as determined by the absence of blood flow
velocity and the presence of initial ST-segment changes and
evolving Q-waves on the subsequent days of observation. The
absence of a bar or lack of representation in the chart
*indicates that the animal has expired. Anodal current vessel
wall injury resulted in complete thrombotic occlusion of the
left circumflex coronary artery in each of eight animals in the
control saline treatment group on day 1 of the experimental
protocol. The mean time to occlusion was 90.4 ± 13.9 min in
the saline-treated dogs. In contrast, those animals receiving
DMP728 maintained patent coronary arteries throughout the
initial 6 h period of observation. Each of the animals treated
with DMP728 was alive on day 2 of the protocol as com-
pared with three of eight (38%) animals in the saline-treated
group. Among the survivors in the control group, one animal
had a measurable blood flow velocity on day 2, but exhibited
electrocardiographic signs of myocardial infarction. The
remaining two animals had persistent thrombotic occlusion
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Figure 4 (a) The blood flow velocity measured in left circumflex
coronary arteries in animals that received saline before application of
the anodal current (180min, 150j9A) to the intimal surface of the
artery. Values are shown for each animal at baseline and 360min
after application of the electrolytic current and induction of vessel
wall injury. Occlusive thrombus formation developed in seven of
eight dogs before the end of the 360 min protocol on day 1. None of
the control dogs survived on the day 6 time point. (b) Coronary
artery blood flow velocity for dogs given DMP728 (I mg kg-', i.v.)
before the induction of vessel wall injury. Platelet inhibition with
DMP728 limited thrombus formation and prevented the subsequent
reduction in blood flow. Flow was maintained during the next 5 days
in all but one dog, which died suddenly in the early hours of day 5.
injury and/or infarction. Only one of the saline-treated
animals was alive on day 3, but by day 4 had expired
suddenly. In contrast, each of the animals in the DMP728
group had patent coronary arteries on each of the subsequent
days. One dog died suddenly between day 4 and 5, and this
was the only death in the DMP728-treated animals. Survival
over the course of the 6 day protocol was 88% for the
DMP728 treatment group, which different significantly from
the control group (P<0.05, Fisher's exact).
Thrombus weight Thrombus weight was reduced signifi-
cantly in the group of animals treated with DMP728 when
compared with the thrombi removed from the control
animals (DMP728 = 1.7 ± 0.4 mg and controls = 20.7 ± 5.0
mg). The thrombi were removed either after spontaneous
death of the animal or at the time of euthanasia on the sixth
day. The data with respect to thrombus weights should be
interpreted with caution, however, because the age of the
individual thrombi differs from animal to animal and the
contribution of the endogenous fibrinolytic system to further
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Figure 5 Diagram representing the patency status of left circumflex
coronary arteries during the experimental protcol. Each horizontal
bar represents one dog over 36 min on day 1; individual boxes
signify patency status on days 2-6. (a) Dogs in the control group
given saline. The animals shown in (b) received DMP728 (1.0mg
kg-', i.v.) before the start of anodal current application. Open or
white bars represent patent arteries; hatched bars signify thrombotic
occlusion; the absence of a bar indicates that the dog has died.
modification of the residual thrombus is uncertain. The
thrombi removed from dogs receiving DMP728 were ob-
tained on the sixth day with the exception of one animal
which died suddenly on the fourth day of the protocol.
Infarct size Each of the eight dogs in the control group
exhibited evidence of extensive irreversible myocardial injury
as determined by the tetrazolium method. Evidence of
myocardial infarction was absent in three of the eight
DMP728-treated animals, and overall infarct size was re-
duced significantly compared with the control group. Infarct
size expressed as a percentage of the left ventricle was
1.7 ± 0.8% in the DMP728-treated group vs 27.5 ± 4.5% in
the control group. The observations correlate with the results
reported for thrombus weight and the incidence of mortality.
Infarct size was expressed as a percentage of the total left
ventricle. Therefore, caution should be used when inter-
preting the results on infarct size since determination of
neither collateral blood flow nor area at risk was made owing
to the limitations imposed as a result of the experimental
protocol.
Protocol 2: prevention of rethrombosis after
rt-PA-induced thrombolysis
A total of 17 dogs was used in this arm of the study. Eight of
the dogs were assigned to each of the treatment groups,
either saline or DMP728. One animal from the control group
was excluded owing to the presence of heart worms upon
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Figure 6 Diagram representing the patency status of left circumflex
coronary arteries during the experimental period. Each horizontal
bar represents one dog over 360 min on day I with zero time equal
to the start of rt-PA infusion. Individual boxes indicate the patency
status on days 2-6. (a) Dogs receiving rt-PA + saline. The animals
shown in (b) received DMP728 (1.0mg kg-', i.v.) as adjunctive
therapy with rt-PA. Open or white bars represent patent arteries;
hatched bars signify thrombotic occlusion; the absence of a bar
indicates that the animal had expired.
coronary artery blood flow velocity were not different
between groups at baseline. The administration of DMP728
had no effect on either mean arterial blood pressure or heart
rate.
Platelet aggregation studies Ex vivo platelet aggregation in
response to adenosine diphosphate (ADP) or arachidonic
acid was determined at baseline and again at 30 and 300 min
after DMP728 or saline administration. Aggregations were
repeated on the subsequent days 2-6. Aggregation to each
agonist was prevented on day 1 among the animals receiving
DMP728. As in protocol 1, ex vivo platelet aggregation
responses returned to baseline values within 24 h and re-
mained consistent over the subsequent study days. The ex
vivo platelet aggregation responses in PRP from the saline-
treated animals did not differ from baseline at any time point
in the study.
Thrombosis/thrombolysis/rethrombosis The patency status of
the left circumflex coronary artery of individual animals in
each group over the 6 day experimental period is represented
in Figure 6 (a and b). As before, open bars signify that the
coronary artery is patent. The hatched bars represent throm-
botic occlusion of the coronary artery as indicated by the
absence of a Doppler flow signal and the presence of elec-
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waves indicative of myocardial ischaemia or cell death
respectively. The absence of a bar signifies that the animal
expired suddenly and unexpectedly. All vessels became occ-
luded in response to anodal current application and all
arteries became patent with a restoration of blood flow after
administration of rt-PA (1.44mgkg-', i.v.) Reocclusions,
characterized by oscillatory patterns of blood flow, of vary-
ing durations occurred in six of the eight saline-treated con-
trol animals. In contrast, oscillatory blood flow did not occur
in the drug-treated animals and occlusive rethrombosis
developed in only one of the dogs receiving DMP728. On
day 2, only one of eight saline-treated animals had survived,
whereas seven of eight dogs in the DMP728-treated group
(P <0.05, Fisher's exact) were alive. Of the remaining
animals in the DMP728-treated group, all but one survived
to the end of the sixth day. One animal died suddenly
between day 4 and day 5.
Time to thrombolysis The time to thrombolysis, defined as
the restoration of coronary artery blood flow velocity to 20%
of the baseline, was determined in each of the animals.
Treatment with DMP728 during the administration of rt-PA
was associated with a decrease in the time to reperfusion
when compared with the group of animals receiving rt-PA
plus saline (rt-PA + DMP728 (1.0mg kg-', i.v. = 9.9 ± 2.2
min vs rt-PA + saline = 18.4 ± 2.3 min; P<0.05).
Residual thrombus size GPIIb/IIIa receptor antagonism with
DMP728 showed a trend towards reduced residual thrombus
weight. The thrombi were removed either after spontaneous
death of the animal or at the time of euthanasia on day 6.
Thrombus weights in the DMP728 group were smaller, but
the difference was not significant (saline = 7.1 ± 1.8 mg;
DMP728 = 2.8 ± 1.0 mg, P = NS). The comparison of
thrombus weights, however, should be viewed with caution
when interpreting data from these measurements owing to
the varying time points at which the thrombi were recovered
relative to the time of thrombus formation.
Infarct size Myocardial infarct size, expressed as a percen-
tage of left ventricular mass averaged, 17.9 ± 2.9% in the
controls vs 6.6 ± 1.7% in the DMP728-treated group (P<
0.05). Adjunctive therapy with DMP728 was associated with
a reduction in the extent of irreversible myocardial damage
as compared with animals in the saline-treated control group.
Discussion
Interruption in the continuity of the endothelial surface of a
normal blood vessel initiates the primary haemostatic res-
ponse to injury invoking platelet activation accompanied by
a localized vasoconstriction (Marcus, 1991) and cyclic flow
variations in stenosed and endothelium-injured vessels media-
ted by platelet aggregates (Yao et al., 1993). Endothelial cell
injury leads to the exposure of subendothelial collagen fibrils
that serve as an agonist for platelet activation and release of
additional agonists including adensoine diphosphate, throm-
boxane and serotinin (Kroll & Schafer, 1989). The recruit-
ment of additional platelets to the primary layer of adherent
platelets forms the haemostatic plug. Concomitant with the
activation and adhesion of platelets there is initiation of the
coagulation cascade and generation of thrombin at the site of
vessel injury. Thrombin is the catalyst for conversion of
fibrinogen to fibrin. In addition, thrombin is a potent agonist
for platelet activation (Marcus & Safier, 1993). The response
to the agonistic potential of a deep vascular lesion differs
from that occurring in response to normal haemostasis in
injured, but otherwise healthy, vessels. Pathological or occ-
lusive arterial thrombi that form in response to a severe
arterial lesion may have the morphological features of a
haemostatic plug, but involve far more platelet adhesion,
activation, recruitment and consolidation (Marcus & Safier,
1993). Development of pathological arterial thrombi is the
result of multiple factors required for induction, assembly
and stabilization of the occlusive mass at the site of extensive
vessel wall injury. The difficulty in preventing occlusive
arterial lesions may be the result of the multifactorial nature
of the arterial thrombotic process.
A further complication arises from the fact that throm-
bolytic agents activate platelets (Fitzgerald et al., 1988a,b) as
a result thrombin activation (Fitzgerald et al., 1988b) or the
effects of plasmin generation (Guccione et al., 1985; Schafer
et al., 1986). The outcome of thrombolytic therapy is
determined, in part, by the relative influences of the local
proaggregatory and antiaggregatory factors exerted upon the
circulating platelets and the residual vascular lesion. The
circulating platelets have an important role in rethrombosis
owing to their ability to be activated by the residual throm-
bus as well as by local thrombin and plasmin generation in
response to lytic therapy (Guccione et al., 1985; Schafer et
al., 1986; Fitzgerald et al., 1988a). The final common path-
way in the formation of a platelet aggregate is the cross-link-
ing of adjacent activated platelets by binding of fibrinogen to
the platelet GPIIb/IIIa receptor complex (referred to in the
integrin nomenclature, as zIIbP3) (Phillips et al., 1987; Gatter
et al., 1988; Keiffer & Phillips, 1990; Kieffer et al., 1992).
Theoretically, the prevention of occlusive arterial lesions may
be achived by modulating the reactivity of the blood platelet
by inhibiting interaction of the GPIIb/IIIa receptor with its
ligand.
GPIIb/IIIa is the most abundant of the platelet integrins
and is found only on platelets and cells of megakaryoblastic
potential. GPIIb/IIIa becomes a receptor for a number of
soluble adhesive proteins (fibrinogen, von Willebrand factor,
vitronectin, fibronectin) via interaction with the Arg-Gly-Asp
(RGD) recognition sequence (Ginsbger et al., 1988a,b).
There is compelling evidence that adhesive proteins bin-
ding to the GPIIb/IIIa complex and that platelet aggregates
are integral components of thrombus formation in vivo (Col-
ler, 1990; 1992). The GPIIb/IIIa complex provides a logical
site for pharmacological interventions directed towards an
inhibition of platelet aggregation and arterial thrombus for-
mation. Several RGD-containing peptides, either synthetic or
derived from snake venoms (disintegrins), are known to
block fibrinogen binding and to prevent the formation of
platelet thrombi (Cadroy et al., 1989; Dennis et al., 1990;
Gould et al., 1990; Tschopp et al., 1993). Furthermore,
blockade of the GPIIb/IIIa receptor with monoclonal anti-
bodies has proved to be antiaggregatory in experimental
(Mickelson et al., 1990a,b; Bates et al., 1991; Rote et al.,
1994a) and clinical studies (Coller, 1990; 1992; Gold et al.,
1990; Kleiman et al., 1993). More recently, peptidomimetic
and non-peptide RGD mimetics have been developed in an
effort to achieve greater antithrombotic potency and selec-
tivity at the site of the GPIIb/IIIa receptor (Kouns et al.,
1992; Peerlinck et al., 1993; Rote et al., 1993; Roux et al.,
1993). The present study provides experimental findings with
DMP728, a non-peptidomimetic antagonist of the platelet
GPIIb/IIIa integrin receptor. The intravenous administration
of a single 1.0 mg kg-', dose of DMP728 prevented primary
thrombus formation in response to deep arterial wall injury
as well as rethrombosis after successful thrombolysis in a
chronic canine model. The comparison between the control
and drug-treated animals subjected to primary thrombosis or
rethrombosis demonstrates the importance of modulating
platelet reactivity by virtue of inhibiting the platelet GPIIb/
IlIa receptor.
The first experimental protocol was designed to determine
if DMP728 could prevent occlusive thrombus formation in
response to severe arterial wall injury (primary thrombosis).
The study was initiated in the instrumented, closed-chest,
anaesthetized dog in which electrolytic injury of the left
circumflex coronary artery was induced in either control
saline-treated animals or in animals pretreated with DMP728
administered as a single intravenous dose of 1.0 mg kg- . The
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dose of DMP728 was selected on the basis of previous
studies in which it was found to prevent rethrombosis in a
canine model of arterial thrombosis and thrombolysis (Mou-
sa et al., 1994; Rote et al., 1994a,b). The animals were
monitored continuously for 6 h on the first day of the pro-
tocol and on each of the subsequent 5 days. The results
indicate that DMP728 prevented primary thrombus forma-
tion. The protective effect persisted for the duration of the
protocol despite the presence of a deep arterial wall lesion
and the return to control values of ex vivo platelet reactivity
within 24 h after drug administration. The results in the
saline-treated control are in marked contrast. Each of the
control animals developed an occlusive thrombus in response
to electrolytic injury of the arterial wall. The occurrence of
sudden death due to ventricular fibrillation within the first
24 h was more common in the control group than in the
DMP728-treated animals. Overall survival at the end of the 6
day protocol was improved significantly in the DMP728-
treated animals as compared with the saline-treated controls.
The observed long-term beneficial effects of DMP728 were
obtained despite the fact that platelet reactivity, as assessed
by ex vivo aggregation, was not inhibited beyond the first
24h after drug administration. Thus, thrombus formation
did not develop over the subsequent 5 days in the DMP728-
treated animals, suggesting that the injured vessel wall had
lost its potential as a thrombogenic site. As would be
expected, thrombus weight and, in particular, infarct size
were reduced significantly in animals receiving DMP728 as
compared with the saline-treated control group.
The results of the present study are in accord with our
earlier observations (Bates et al., 1992) demonstrating that
temporary, but complete, inhibition of the platelet GPIIb/
MIla receptor for several hours after deep arterial wall injury
significantly reduced later intravascular thrombus formation
and thrombotic occlusion. The long-term prevention of
primary thrombus formation by selective inhibition of the
GPIIb/IIIa receptor in a chronic model of severe vessel wall
injury illustrates the important role of the platelet glyco-
protein receptor as a mediator of thrombus formation.
Temporary inhibition of the GPIIb/IIIa receptor prevents
thrombus formation in contrast to merely delaying the
development of the occlusive lesion. Inhibition of platelet
deposition for 8 h with dipyridamole or prostacyclin after
percutaneous balloon de-endothelization rendered rabbit aor-
tae non-reactive to circulating blood platelets (Groves et al.,
1986). In vivo studies using a reperfusion model demonstrated
that the vessel wall lost the ability to initiate thrombus
formation within 40 min after endothelial injury, thus
emphasizing that platelet deposition and thrombus formation
are time-limited phenomena (Baumgartner, 1973). The exis-
tence of a specific time window in which the injured vessel
wall remains thrombogenic is an important consideration in
designing appropriate dosing regimens and schedules for
prevention of arterial occlusive events, as might develop after
invasive procedures likely to be associated with vessel wall
damage and increased thrombogenicity at the site of injury.
The time-limited duration of the 'window of thrombogen-
icity' may provide a reasonable explanation for why a single
dose of DMP728 was able to prevent primary occlusive
thrombus formation. Whether or not the same 'window of
thrombogenicity' will apply to clinical situations of coronary
artery thrombolysis or coronary angioplasty remains to be
determined, especially in light of recent information sugges-
ting the need for prolonged platelet inhibition by the
chimeric 7E3-Fab antibody after thrombolytic therapy (Klei-
man et al., 1993).
The second phase of our study evaluated the ability of
DMP728 to prevent rethrombosis after successful throm-
bolysis in a chronic canine model. Thrombolysis and
recanalization of the affected vessel was achieved readily in
all animals after the intravenous administration of rt-PA. As
observed in previous studies (Mickelson et al., 1990a), using
the same experimental procedure, thrombolysis with rt-PA,
in the absence of adjunctive therapy, was accompanied by
repetitive episodes of oscillatory variations in coronary artery
blood flow. The erratic flow pattern was characterized by
periods of total cessation of blood flow followed by periods
of reactive hyperaemia, eventually culminating in sudden
arrhythmic death or total thrombotic occlusion within the
first 24 h. In the present study, only one of eight saline-
treated control animals undergoing thrombolysis maintained
a patent circumflex coronary artery and survived the subse-
quent 5 days of the study protocol. Seven of the eight
DMP728-treated animals maintained patent vessels apd sur-
vival was improved significantly as compared with the con-
trol group.
The present study was not designed to assess the influence
of DMP728 upon rt-PA-induced thrombolysis. It became
apparent, however, that the administration of the GPIIb/IIIa
receptor antagonist 5 min after completion of the rt-PA
infusion, but before recanalization had occurred, significantly
decreased the time needed to achieve thrombolysis. There-
fore, the treatment regimen consisting of rt-PA followed by
the intravenous administration of 1.Omgkg-' of DMP728
accelerated recanalization of the occluded vessel and signifi-
cantly reduced both the incidence of reocclusion and death.
Furthermore, the extent of irreversible myocardial tissue
injury was reduced significantly in the animals treated with
DMP728. In addition to being involved in thrombus forma-
tion, aggregating platelets can initiate intense vasoconstric-
tion after the activation and release of potent vasoactive
mediators (Saldeen et al., 1993; Yao et al., 1993). Infarct size
expansion is related to the extent of platelet accumulation in
myocardium that has undergone reperfusion in the presence
of a critical stenosis (Rousseau et al., 1993). The beneficial
effect on the salvage of myocardial tissue, after inhibition of
the GPIIb/IIIa receptor, may derive, in part, from the fact
that coronary artery blood flow is maintained and not com-
promised by repetitive episodes of oscillatory blood flow
commonly observed after thrombolysis in the absence of
adjunctive anti-platelet therapy.
A recent study (Kohmura et al., 1993) assessed the effect of
an initial single intravenous bolus injection of chimeric 7E3-
Fab followed by repeated bolus injections of rt-PA on reper-
fusion and reocclusion in heparinized baboons with a
femoral arterial thrombosis with superimposed high-grade
stenosis. The presence of the platelet GPIIb/IIIa receptor
antagonist, chimeric 7E3-Fab, decreased the time to recanal-
ization and sustained femoral artery blood flow in contrast to
control animals receiving saline or aspirin as the adjunctive
treatment. In addition, it has been reported that concomitant
systemic therapeutic heparin anticoagulation is required for
the maximal effect of 7E3 (Yasuda et al., 1990). A major
difference between the previous study (Kohmura et al., 1993)
and the present investigation is that we did not use heparin.
Despite the absence of heparin in the present study, DMP728
was capable of decreasing the time to clot lysis. Whether or
not heparin is necessary for attaining beneficial effects with
other inhibitors of the platelet glycoprotein IIb/IIIa receptor
requires further investigation. With the exception of enhanc-
ing the apparent time to clot lysis, DMP728 provided
beneficial effects identical to those observed in a previous
study (Mickelson et al., 1990a) in which 7E3 F(ab')2 was
administered after rt-PA in a chronic canine model of cor-
onary artery thrombosis and thrombolysis. As in the present
study, 7E3 F(ab')2 administration resulted in a preservation
of vessel patency and abolition of repetitive oscillatory flow
in the severely injured circumflex coronary artery. The pres-
ent results complement the recent observations (Mousa et al.,
1994) and provide additional insight into the efficacy of
DMP728 as an antithrombotic agent in a chronic model of
vessel wall injury. DMP728 in a dose of 1.0 mg kg-'
prevented both primary and secondary thrombus formation
when used as the sole anti-platelet agent and was fully
effective in the absence of heparin or antithrombins. The
dose of DMP728 was the same as that used by Mousa et al.
(1994), who reported that the drug's duration of action and
efficacy in preventing thrombus formation was decreased at
lower doses. A similar dose-response relationship with
respect to the prevention of primary and secondary throm-
bosis was reported by Rote et al. (1994).
The ability of inhibitors of the platelet glycoprotein Ilb/
I11a receptor to maintain vessel patency when used as the
sole adjunctive agent in combination with thrombolytic
therapy provides compelling evidence that the platelet plays a
major role in rethrombosis. Platelets are activated during
thrombolysis (Coller, 1990), and the residual thrombus along
with the stenotic lesion present a thrombogenic substrate for
recruitment of new platelets and fibrin deposition leading to
rethrombosis. Thrombolysis therefore, is accompanied by a
dynamic interaction in which local lytic and thrombogenic
activity occur simultaneously. Inhibition of the platelet
GPIIb/IIIa receptor shifts the equilibrium so that lytic
activity predominates, thereby maintaining blood flow and
permitting time for the residual thrombus and injured vessel
to become non-thrombogenic.
Critique of the experimental model
The original electrically induced coronary artery thrombosis
model in the canine heart employed alternating current de-
livered to the vascular lumen through a catheter electrode
positioned in the coronary artery under fluoroscopic control
(Salazar, 1961). The experimental model used in this study
was described previously (Romson et al., 1980). Since it was
first described, the model has been used by several inves-
tigators to examine a variety of anti-platelet interventions for
the prevention of primary thrombus formation (Fitzgerald et
al., 1986; Mickelson et al., 1990b; Rote et al., 1993) or
prevention of rethrombosis after successful thrombolysis
(Mickelson et al., 1990a; Rote et al., 1993; 1994a; Saldeen et
al., 1993; Tschopp et al., 1993). The arterial wall lesion and
subsequent formation of an occlusive thrombus result from
direct application of an anodal direct current to the endothe-
lial surface of the vessel, leading to exposure of proaggre-
gatory subendothelial elements (Mickelson et al., 1990b;
Bates et al., 1992). The resulting thrombus consists of a
platelet-fibrin mass adherent to the vessel wall at the site of
intimal injury (Romson et al., 1980) and possess the morpho-
logical features of acutely formed thrombi found in patients
with acute myocardial infarction (Falk, 1985). The cellular
composition of the arterial thrombus is an important con-
sideration in the interpretation of data derived from experi-
mental studies. Erythrocyte-rich coronary arterial thrombi
are consistently lysed after an intravenous infusion of rt-PA,
whereas platelet-rich thrombi are relatively resistant to lysis
even in the presence of high doses of a thrombolytic agent
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(Fitzgerald et al., 1988a). It is recognized, however, that the
experimental model lacks the atherosclerotic lesions that are
prominent in most, if not all, diseased human arteries in
which thrombus formation occurs. The inability to replicate
the entire human clinical pathophysiological state may sug-
gest that prevention of rethrombosis in a diseased human
artery with atherosclerosis may not be prevented to the same
degree as in the experimental animal.
An important feature of the experimental model is that it
permits an extended period of observation in contrast to an
acute animal model. During the subsequent days, one can
evaluate the efficacy of a selective intervention with respect to
preventing thrombus formation and determine the duration
for maintaining inhibition of the GPIIb/IIIa receptor during
which time the thrombogenic focus undergoes resolution and
becomes non-thrombogenic. A minor limitation in the
chronic animal model is the inability to evaluate bleeding
times by the Simplate method owing to the humane concerns
for the welfare of the experimental animal.
Summary
DMP728 is among the first of a new series of non-peptide,
low molecular weight compounds designed to inhibit the
platelet GPIIb/IIIa receptor. The present study, conducted in
the chronically instrumented canine, demonstrates that DMP
728 is effective in preventing occlusive arterial thrombosis in
response to severe vessel wall injury and to prevent rethrom-
bosis after successful thrombolytic therapy. In both instances,
DMP728 was administerd once as an intravenous dose of
1.0 mg kg-'. DMP728, as the singular adjunctive agent, pro-
vided prolonged protection in terms of maintaining vessel
patency and reducing mortality. Although the platelet GPIIb/
IlIa receptor may appear to be a logical target site for
therapeutic intervention in thromboembolic disease, the
safety and efficacy of this class of agent will be determined by
the outcome of well-designed clinical trials in man. The
recently reported clinical results (Kleiman et al., 1993) with a
platelet GPIIb/IIIa receptor antagonist (monoclonal antibody
7E3-Fab) administered after thrombolytic therapy suggest
that inhibition of the platelet integrin receptor has thera-
peutic potential. DMP728 provides an alternative interven-
tion by which the concept can be evaluated further in both
basic and clinical studies.
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